{"id":"W4389488043","doi":"10.1016/j.iotech.2023.100537","title":"65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Docetaxel; Medicine; Lenvatinib; Oncology; Chemotherapy; Internal medicine; Lung cancer; Phases of clinical research; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006305632,0.0005054331,0.001425831,0.0009695114,0.00025716,0.00002048339,0.0003580751,0.0005283433,0.00007846915],"category_scores_gemma":[0.0001043985,0.0004520815,0.0001922571,0.001004096,0.0005643222,0.00008458404,0.0001402249,0.0005437829,0.000003824981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000536883,"about_ca_system_score_gemma":0.0007845883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002478348,"about_ca_topic_score_gemma":0.0002638332,"domain_scores_codex":[0.997198,0.0001002268,0.0008653952,0.0007743707,0.0002653164,0.0007967271],"domain_scores_gemma":[0.9977129,0.0006392341,0.0006901867,0.0006811291,0.0001951902,0.00008140013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2905379,0.005673955,0.007625679,0.0009205259,0.005150198,0.000357731,0.01799028,0.00002999629,0.3854115,0.0001112738,0.002667592,0.2835234],"study_design_scores_gemma":[0.6193648,0.09214257,0.00325797,0.000783885,0.001804531,0.0001676679,0.04153956,0.002983197,0.2247319,0.0001125282,0.01197784,0.001133568],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879132,0.003296883,0.0001138127,0.001940431,0.0008355594,0.005178561,0.00005466001,0.0003898257,0.0002770488],"genre_scores_gemma":[0.9949264,0.0008602545,0.0007256438,0.0003061582,0.0001030817,0.002622692,0.00005046135,0.0001067511,0.0002985484],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3288269,"threshold_uncertainty_score":0.9997931,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04270142033337985,"score_gpt":0.3679328438520774,"score_spread":0.3252314235186975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}